Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) experienced a dramatic surge in its stock price on Wednesday, July 22, 2026, following an update on its Nu-3 antibiotic program. Shares soared 143.5% to $4.53 by 10:05 a.m. EDT, after hitting a session high of $7.13 earlier in the day. The move was accompanied by extraordinary trading volume of 58.1 million shares, approximately 232 times the stock's visible average daily volume.
The surge was company-specific, as the broader biotech sector, represented by the SPDR S&P Biotech ETF (NYSEARCA: XBI), slipped 0.6% during the same period. This divergence underscores that the catalyst is tied directly to Lakewood-Amedex's developments rather than a sector-wide rally.
Wednesday's update reiterated the core 21-day test protocol initially introduced on May 1, 2026. The company stated that the minimum inhibitory concentration (MIC) for E. coli increased modestly in May, while no change was observed for MRSA. In comparison, control groups treated with ciprofloxacin demonstrated resistance increases of over 2,000-fold and 600-fold, respectively, highlighting Nu-3's potential advantage in combating antibiotic resistance.
The update also included the addition of a policy link and expanded in-vitro profiling, outlining activity across multiple resistance mechanisms. However, no new patient data were presented. Chief Executive Kelvin Cooper reiterated that Nu-3 "targets and disrupts bacterial membranes through a unique, physical mechanism of action," though this claim remains supported only by laboratory-based evidence.
Investors are closely watching the upcoming Phase 2a study. According to management's initial schedule, the first patient visit is planned for the third quarter of 2026, with top-line results expected by late 2026 or early 2027. The company's cash position stood at $11,709 as of March 31, 2026, supplemented by approximately $6.8 million in net proceeds from convertible preferred stock. Management believes this funding will sustain operations through 2026.
The turnover ratio, based on Lakewood's June filing with a post-split share count of approximately 1.75 million, indicates that trading volume on Wednesday was 33.2 times the available float. Trading on a split-adjusted basis began on June 22. This figure is an initial estimate, as subsequent conversions could raise the present total.
Despite the excitement, risks remain elevated. The next significant challenge for investors will be clinical performance. Data from the next patient group in Phase 2a is still pending, and there is a possibility that preclinical results may not translate to human efficacy. Additionally, favorable conversions of convertible preferred stock could result in dilution for existing shareholders.
The broader context includes recent discussions by PACCARB, the federal advisory council on combating antibiotic-resistant bacteria, which convened on June 16. According to the Department of Health and Human Services, the council contributed recommendations for the government's action plan covering 2026-2031, underscoring the policy tailwinds for companies like Lakewood-Amedex focused on novel antibiotics.
